Active Biotech Q3 net loss widens 38% year over year to SEK 8.3 million
Bitget2026/11/05 07:35- Active Biotech’s third-quarter 2026 net loss widened 38% year over year to SEK 8.3 million.
- Operating expenses rose 42% to SEK 8.5 million year over year, while no net sales were recorded.
- Cash and cash equivalents fell 44% from year-end 2025 to SEK 36.3 million at September 30, 2026.
- The first cohort under the amended HOVON 172 myelofibrosis protocol completed safety evaluation in October; enrollment continued.
- A new collaboration with MPN-RC expanded US development activities for tasquinimod in myelofibrosis.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barrick’s Marquee gold project faces hazy study timing
Japanese and South Korean stock markets open
Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.
Crypto prices
More
